Precision Oncology
Next-generation tyrosine kinase inhibitors for precision medicine. Advanced targeted therapies for specific cancer molecular profiles.
Explore our portfolio of 3 high-quality oncology products designed to meet the highest international standards.
Second-generation BCR-ABL tyrosine kinase inhibitor. Dual SRC/ABL inhibitor for CML with imatinib resistance.
Indications:
Highly selective second-generation BCR-ABL inhibitor with improved potency for CML treatment.
Indications:
Expanding portfolio of kinase inhibitors and precision medicine for molecularly-defined cancer subtypes.
Indications:
Our commitment to quality is backed by international certifications and regulatory compliance across multiple markets.
Available
Products manufactured at WHO Good Manufacturing Practice certified facilities
36AARCP2455C1Z8
Registered for Goods and Services Tax in India
UDYAM-TS-02-0354028
Micro, Small and Medium Enterprises registration
Just say available
Central and state drug regulatory approvals in India
International regulatory submissions for major markets
Interested in our oncology products? Contact us for product catalogs, regulatory documentation, or partnership opportunities.
Oncology product development and registration
Technology transfer and formulation development
Contract manufacturing partnerships with WHO-GMP facilities
Regulatory dossier support for FDA, EMA, TGA, COFEPRIS and Asian markets
Licensing and distribution partnerships globally
Contact our team for detailed product specifications, regulatory documentation, or partnership opportunities.